A major international Phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab—a medication already prescribed to some patients with MS—significantly slows disability progression in people ...
May 28, 2026
0
5
The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of Roche's top-selling drug ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis (PPMS)—a form of MS thought to ...
Apr 15, 2026
0
9
New research presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) demonstrates that ocrelizumab provides superior control of multiple sclerosis (MS) relapses ...
Sep 23, 2025
0
15
When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered patients immense hope. The long-awaited drug is a monoclonal antibody that depletes B cells—the immune ...
Jul 2, 2025
0
22
Researchers at the University of Colorado Anschutz Medical Campus have uncovered a critical, previously underappreciated role for B cells in vaccine protection. Best known for producing antibodies, B cells also guide other ...
Apr 23, 2025
0
20
For patients with primary progressive multiple sclerosis (PPMS), the time to confirmed disability progression (CDP) does not differ for those who are anti-CD20-treated and untreated, according to a study published online ...
Sep 26, 2024
0
47
In people with primary progressive multiple sclerosis (MS), a new study has found no difference in the amount of time before disability worsened between people taking certain medications and those not receiving treatment. ...
Sep 25, 2024
0
40
New research presented today at European Committee for Treatment and Research in Multiple Sclerosis 2024 reveals that initiating monoclonal antibody therapy during childhood, rather than delaying treatment until early adulthood, ...
Sep 17, 2024
0
49
Multiple sclerosis (MS) is a disease that looks different in everyone who has it—and you may know more people who have it than you think.
Mar 5, 2024
0
40
Certain medications for multiple sclerosis (MS) called monoclonal antibodies, taken while breastfeeding, may not affect the development of a child during the first three years of life, according to a preliminary study presenting ...
Mar 4, 2024
0
32
